首页分子通化学资讯化学百科反应查询关于我们

请输入关键词

历史搜索

热门化合物HOT

喹啉
水杨醛
二溴甲烷
谷胱甘肽
L-乳酸
苯巴比妥
辣椒碱
非那明
百草枯
联苯烯

allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate | 1161921-53-4

分子结构分类

有机化合物 - 苯类化合物 - 苯和取代衍生物

中文名称

——

中文别名

——

英文名称

allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate

英文别名

(S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid, allyl ester；prop-2-enyl (6S)-6-(4-cyano-2-methylsulfonylphenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate

allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate化学式

CAS

1161921-53-4

化学式

C₂₄H₂₀F₃N₃O₅S

mdl

——

分子量

519.501

InChiKey

OBTQYBNHHLMLID-OAQYLSRUSA-N

BEILSTEIN

——

EINECS

——

物化性质

沸点：

704.0±60.0 °C(Predicted)
密度：

1.45±0.1 g/cm3(Predicted)

计算性质

辛醇/水分配系数(LogP)：

3.2
重原子数：

36
可旋转键数：

7
环数：

3.0
sp3杂化的碳原子比例：

0.21
拓扑面积：

125
氢给体数：

1
氢受体数：

9

上下游信息

上游原料

中文名称	英文名称	CAS号	化学式	分子量
——	allyl 4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1161921-52-3	C₂₄H₂₀F₃N₃O₅S	519.501
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid	1161921-94-3	C₂₁H₁₆F₃N₃O₅S	479.436
——	(rac)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetra-hydropyrimidine-5-carboxylic acid	——	C₂₁H₁₆F₃N₃O₅S	479.436

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	2-Hydroxyethyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1164204-11-8	C₂₃H₂₀F₃N₃O₆S	523.49
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid	1161921-94-3	C₂₁H₁₆F₃N₃O₅S	479.436
——	(S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid	1164203-73-9	C₂₅H₂₂F₃N₃O₅S	533.528
——	2-Hydroxyethyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1164204-19-6	C₂₄H₂₂F₃N₃O₆S	537.516
——	(S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid	1164204-90-3	C₂₂H₁₈F₃N₃O₅S	493.463
——	2,3-dibromopropyl (4S)-6-(bromomethyl)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1164204-46-9	C₂₅H₂₁Br₃F₃N₃O₅S	772.232
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide	1161921-54-5	C₂₁H₁₇F₃N₄O₄S	478.452
——	Allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-3-(methylsulfonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1164204-14-1	C₂₅H₂₂F₃N₃O₇S₂	597.593
——	2-Hydroxyethyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-3-(methylsulfonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate	1164204-17-4	C₂₄H₂₂F₃N₃O₈S₂	601.581
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-55-6	C₂₁H₁₅F₃N₄O₃S	460.436
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-6-methyl-3-(methylsulfonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid	1164204-87-8	C₂₂H₁₈F₃N₃O₇S₂	557.528
——	(S)-4-(3,6-dimethyl-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-d]pyrimidin-4-yl)-3-(methylsulfonyl)benzonitrile	1164203-74-0	C₂₃H₁₉F₃N₄O₄S	504.489
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-82-9	C₂₂H₁₇F₃N₄O₃S	474.463
——	(4S)-3-(cyanomethyl)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1164203-60-4	C₂₃H₁₆F₃N₅O₃S	499.473
——	(6S)-5-Cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-carboxamide	1161921-57-8	C₂₅H₂₂F₃N₅O₆S	577.541
——	(6S)-5-Cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-carboxamide	1161921-62-5	C₂₆H₂₄F₃N₅O₅S	575.568
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1,3-bis[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1164203-63-7	C₂₈H₁₈F₆N₄O₃S	604.532
——	(4S)-3-[(3R)-3-Aminopiperidin-1-yl]carbonyl-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1164202-26-9	C₂₇H₂₅F₃N₆O₄S	586.595
——	(4S)-4-(4-cyano-2-methylsulfonylphenyl)-6-methyl-2-oxo-3-(thiomorpholine-4-carbonyl)-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile	1164202-30-5	C₂₆H₂₂F₃N₅O₄S₂	589.619
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-3-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1164203-61-5	C₂₈H₁₈F₃N₅O₃S	561.544
——	2-[(6S)-5-cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetamide	1161921-71-6	C₂₃H₁₈F₃N₅O₄S	517.488
——	2-[(6S)-5-cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid	1161921-70-5	C₂₃H₁₇F₃N₄O₅S	518.473
——	2-[(6S)-5-Cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]-N-(2-hydroxyethyl)acetamide	1161921-72-7	C₂₅H₂₂F₃N₅O₅S	561.541
——	tert-butyl [(6R)-5-cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-yl]acetate	——	C₂₇H₂₅F₃N₄O₅S	574.581
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-3-[2-oxo-2-(3-oxopiperazin-1-yl)ethyl]-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-74-9	C₂₇H₂₃F₃N₆O₅S	600.578
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3-{2-[4-(2-hydroxyethyl)piperidin-1-yl]-2-oxoethyl}-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-73-8	C₃₀H₃₀F₃N₅O₅S	629.66
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-3-{2-[4-hydroxypiperidin-1-yl]-2-oxoethyl}-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-75-0	C₂₈H₂₆F₃N₅O₅S	601.606
——	tert-Butyl [(3R)-1-{[(6S)-5-cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl}-3,6-dihydropyrimidin-1(2H)-yl]carbonyl]piperidin-3-yl]carbamate	1164204-42-5	C₃₂H₃₃F₃N₆O₆S	686.712
——	4-nitrophenyl (6S)-5-cyano-6-[4-cyano-2-(methylsulfonyl)phenyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-carboxylate	1161921-95-4	C₂₈H₁₈F₃N₅O₇S	625.541
——	(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-3-(methylsulfonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1161921-76-1	C₂₂H₁₇F₃N₄O₅S₂	538.528
——	(4S)-4-[4-Cyano-2-(methylsulfonyl)phenyl]-6-methyl-3-[(4-methylphenyl)sulfonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile	1164203-44-4	C₂₈H₂₁F₃N₄O₅S₂	614.626
——	(4S)-4-(4-cyano-2-methylsulfonylphenyl)-3-(1-ethyl-3-methylpyrazol-4-yl)sulfonyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile	1164203-03-5	C₂₇H₂₃F₃N₆O₅S₂	632.644

反应信息

作为反应物：

描述：

allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate 在溴、 lithium hexamethyldisilazane 作用下，以四氢呋喃、氯仿为溶剂，反应 34.33h，生成 (S)-4-(3,6-dimethyl-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-d]pyrimidin-4-yl)-3-(methylsulfonyl)benzonitrile

参考文献：

名称：

4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE

摘要：

本发明涉及新颖的4-(4-氰基-2-硫代芳基)二氢嘧啶-2-酮衍生物，涉及它们的制备方法，以及它们单独或与其他药物结合用于治疗和/或预防疾病，还涉及它们用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管系统疾病的用途。

公开号：

US20110034433A1
作为产物：

描述：

4-氰基-2-氟苯甲醛在吗啉、盐酸、磷酸三乙酯、四磷十氧化物、 potassium carbonate 作用下，以四氢呋喃、水、二甲基亚砜、异丙醇、丙酮为溶剂，反应 21.5h，生成 allyl (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate

参考文献：

名称：

METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE

摘要：

本发明涉及一种用于制备式(I)的(4S)-4-[4-氰基-2-(甲磺基)苯基]-3,6-二甲基-2-氧代-1-[3-(三氟甲基)苯基]-1,2,3,4-四氢嘧啶-5-碳腈的新型改进方法，以及制备和使用式(I)的(4S)-4-[4-氰基-2-(甲磺基)苯基]-3,6-二甲基-2-氧代-1-[3-(三氟甲基)苯基]-1,2,3,4-四氢嘧啶-5-碳腈的晶型(A)。

公开号：

US20180072685A1

点击查看最新优质反应信息

文献信息

Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases

作者：Franz von Nussbaum、Volkhart M.-J. Li、Swen Allerheiligen、Sonja Anlauf、Lars Bärfacker、Martin Bechem、Martina Delbeck、Mary F. Fitzgerald、Michael Gerisch、Heike Gielen-Haertwig、Helmut Haning、Dagmar Karthaus、Dieter Lang、Klemens Lustig、Daniel Meibom、Joachim Mittendorf、Ulrich Rosentreter、Martina Schäfer、Stefan Schäfer、Jens Schamberger、Leila A. Telan、Adrian Tersteegen

DOI：10.1002/cmdc.201500131

日期：2015.7

Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors
4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use

申请人：Von Nussbaum Franz

公开号：US08889700B2

公开（公告）日：2014-11-18

The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.

本发明涉及新型的4-(4-氰基-2-硫基芳基)二氢嘧啶-2-酮衍生物，其制备方法，它们单独或与其他药物联合用于治疗和/或预防疾病，以及它们的用途用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺和心血管系统疾病。
[DE] 4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINONE UND IHRE VERWENDUNG<br/>[EN] 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF<br/>[FR] 4-(4-CYANO-2-THIOARYLE)-DIHYDROPYRIMIDINONE ET SON UTILISATION

申请人：BAYER SCHERING PHARMA AG

公开号：WO2009080199A1

公开（公告）日：2009-07-02

Die vorliegende Anmeldung betrifft neue 4-(4-Cyano-2-thioaryl)-dihydropyrimidm-2-on-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von Erkrankungen der Lunge und des Herz-Kreislauf-Systems.

这份申请涉及新的4-(4-氰基-2-硫基芳基)-二氢嘧啶-2-酮衍生物，其制备方法，其单独或与其他药物结合治疗和/或预防疾病的用途，以及其用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管系统疾病的药物。
4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF

申请人：Bayer Intellectual Property GmbH

公开号：US20150045344A1

公开（公告）日：2015-02-12

The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.

本发明涉及新型4-(4-氰基-2-硫基芳基)二氢嘧啶-2-酮衍生物，其制备方法，其单独或联合用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺和心血管系统疾病的药物。
4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof

申请人：Bayer Intellectual Property GmbH

公开号：US09174997B2

公开（公告）日：2015-11-03

The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.

本发明涉及新型4-(4-氰基-2-硫代芳基)二氢嘧啶-2-酮衍生物，其制备方法，它们单独或联合用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管系统疾病的药物。